Diagnostic complexities of eosinophilia.

@article{Montgomery2013DiagnosticCO,
  title={Diagnostic complexities of eosinophilia.},
  author={Nathan D. Montgomery and Cherie H. Dunphy and Micah J. Mooberry and Andrew Laramore and Matthew C. Foster and Steven I. Park and Yuri Fedoriw},
  journal={Archives of pathology \& laboratory medicine},
  year={2013},
  volume={137 2},
  pages={
          259-69
        }
}
CONTEXT The advent of molecular tools capable of subclassifying eosinophilia has changed the diagnostic and clinical approach to what was classically called hypereosinophilic syndrome. OBJECTIVES To review the etiologies of eosinophilia and to describe the current diagnostic approach to this abnormality. DATA SOURCES Literature review. CONCLUSION Eosinophilia is a common, hematologic abnormality with diverse etiologies. The underlying causes can be broadly divided into reactive, clonal… 

Figures and Tables from this paper

Primary immunodeficiencies associated with eosinophilia

TLDR
This literature review shows that there is an extensive list of PIDs which have been reported with eosinophilia, which helps clinicians to consider an extended differential diagnoses when tasked with exclusion of PID as a cause for eos inophilia.

Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.

TLDR
Hypereosinophilia and HES are defined by specific clinical and laboratory criteria and molecular testing helps to better subclassify myeloid neoplasms with eosinophile and to identify patients for targeted treatments.

Multi‐system complications of hypereosinophilia

TLDR
This patient’s military history, and associated travel to endemic regions, puts him at risk for helminthic infections such as Strongyloidiasis, Toxocariasis, Trichinellosis, and Hookworm, which should be considered when secondary causes have been ruled out.

Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia

TLDR
An update of the classifications of myeloproliferative disorders associated with hypereosinophilia is discussed together with open and controversial questions and promising results of tyrosine kinase inhibitor treatments are reviewed.

Anaplastic Large Cell Lymphoma with Massive Eosinophilia and Complex Karyotype Initially Misdiagnosed as Chronic Eosinophilic Leukemia

TLDR
A patient with marked proliferation of eosinophils in the peripheral blood and bone marrow (BM) with a complex karyotype is presented, leading to initial misdiagnosis as chronic eOSinophilic leukemia (CEL).

Diagnostic challenges during pretreatment long-term follow-up in a patient with FIP1L1-PDGFRA-positive eosinophilia.

TLDR
The case of a man with myeloid neoplasm and eosinophilia in whom a definitive diagnosis could not be adequately made based on histopathological features is presented who was ultimately diagnosed only after extensive molecular analyses and successfully treated with imatinib.

Primary FIP1L1-PDGFR Positive Hypereosinophilic Syndrome with Unusual Rheumatic Onset

TLDR
Initial symptoms were suggestive for a myopathy, it was difficult to establish the positive diagnosis without any obvious paraclinical data, but further investigations such as MRI and muscle biopsy were conclusive for the diagnosis of Shulman’s eosinophilic fasciitis and clinical improvement was observed after corticosteroid treatment.

Eosinophilia as a first sign of Hodgkin´s lymphoma: A case report

TLDR
Eosinophilia without revealed cause can precede HL so it should be cautious in that mind, and carefull searching for enlarged lymph nodes, anywhere in body is suggested.

Comparison of eosinophil density in staging bone marrow biopsies from Malawi and the United States

TLDR
Specific and relative eosinophil counts in peripheral blood were similar between populations in this study, and baseline clinical and laboratory parameters, including percentage of patients with non-Hodgkin versus Hodgkin lymphoma, were otherwise similar between the populations.

References

SHOWING 1-10 OF 104 REFERENCES

Eosinophilic myeloid disorders: new classification and novel therapeutic strategies

  • J. Gotlib
  • Medicine, Biology
    Current opinion in hematology
  • 2010
TLDR
Molecular/genetic analysis is now mandatory for the diagnosis, classification, and treatment of eosinophilic myeloid disorders and the finding of rearranged, constitutively activated PDGFRA/B identifies patients who are eminently treatable with tyrosine kinase inhibitors.

Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.

TLDR
A simplified algorithm for distinguishing the various causes of clonal and idiopathic eosinophilia is provided and current therapy is discussed, including new drugs (imatinib mesylate, alemtuzumab, and mepolizumab).

Practical approach to the patient with hypereosinophilia.

Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.

The hypereosinophilic syndromes: current concepts and treatments

TLDR
A recent study showed that a monoclonal antibody to IL‐5, mepolizumab, reduced glucocorticoid therapy in HES patients who did not possess the FIP1L1‐PDGFRA mutation while controlling eosinophilia and preventing recurrence or progression of tissue damage.

Pathogenesis of Hyper IgE Syndrome

TLDR
In depth study of the role of STAT3 mutations in specific aspects of HIES may lead to better understanding and new approaches to treatment of conditions intrinsic to HIES that are common in the general population, such as staphylococcal infections, scoliosis, osteoporosis, bronchiectasis, and arterial aneurysms.

HEREDITARY EOSINOPHILIA: REPORT OF A FAMILY AND REVIEW OF THE LITERATURE.

SINCE 1909 (Gaugain), there have been numerous reports of familial occurrence of persistent eosinophilia in the absence of known causal factors. These have generally been called "constitutional" or

The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

TLDR
The identification of a constitutively activated fusion tyrosine kinase on chromosome 4q12, derived from an interstitial deletion, that fuses the platelet-derived growth factor receptor-alpha gene (PDGFRA) to an uncharacterized human gene FIP1-like-1 (FIP1L1).

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

TLDR
The identification of a constitutively activated fusion tyrosine kinase on chromosome 4q12, derived from an interstitial deletion, that fuses the platelet-derived growth factor receptor-alpha gene (PDGFRA) to an uncharacterized human gene FIP1-like-1 (FIP1L1).

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.

...